BBOT Earnings Date: Nov 11, 2026 (Estimated) — BridgeBio Oncology Therapeutics Inc.
NASDAQ
Updated
When is BBOT's next earnings date?
BridgeBio Oncology Therapeutics Inc. (BBOT) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.69.
How did BBOT do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), BridgeBio Oncology Therapeutics Inc. posted EPS of -$705.20 versus the -$0.56 estimate, a miss of 130492.6%. Revenue was $0. The stock's 1-day post-earnings move was +2.4%.
How much does BBOT stock move after earnings?
BBOT beat EPS estimates in 1 of its last 4 reported quarters. Over the last 4 reports the stock moved an average of 2.6% (up or down) in the day after earnings.
About BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.56 | -705.20 | -130492.59% | $0 | ❌ Miss | +2.39% | -2.72% | -40.00% |
| 2026-05-12 | Q1 2026 | -0.51 | -526.11 | -103058.83% | $0 | ❌ Miss | -0.61% | +7.26% | -8.24% |
| 2026-03-05 | Q4 2025 | -0.66 | -0.49 | +25.76% | $0 | ✅ Beat | +5.36% | -7.68% | -9.91% |
| 2025-11-12 | Q3 2025 | -0.37 | -1.03 | -178.38% | $0 | ❌ Miss | -1.98% | +0.40% | -0.32% |
Showing last 4 quarters.